Brief: Prothena Q2 Net Income USD -125.767 Million

Prothena

04/08/2025 21:05

Overview

Prothena Q2 net loss $125.8 mln, driven by restructuring charges

Total revenue falls sharply from $132 mln in Q2 2024

Outlook

Prothena anticipates $105 mln in milestone payments in 2026

Company expects 2025 net cash used in operations to be $170-$178 mln

Result Drivers

RESTRUCTURING CHARGES - Net loss driven by $32.6 mln restructuring charges related to birtamimab program discontinuation and workforce reduction

NEURODEGENERATIVE ADVANCEMENTS - Roche advancing prasinezumab into Phase 3 for Parkinson's and initial data from PRX012 Alzheimer's trials expected in August 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Total Revenue
$4.42 mln
Q2 Net Income
-$125.77 mln
Q2 Operating Expenses
$89.04 mln
Q2 Pretax Profit
-$80.96 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Prothena Corporation PLC is $18.00, about 62.2% above its August 1 closing price of $6.81

Press Release: ID:nBw9QWyzja

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)